Avita Medical to Present at SoCalBio Investor Conference & Exhibition
NORTHRIDGE, CA and CAMBRIDGE, UNITED KINGDOM, Nov 05, 2012 (Menafn - MARKETWIRE via COMTEX) --Regenerative medicine company Avita Medical Ltd. (asx:AVH) (otcqx:AVMXY) today announced that it will be presenting at the upcomingSoCalBio Investor Conference & Exhibition. The event will take placeon November 7, 2012 at the Omni Hotel in Los Angeles, California.
The Company will be presenting in the Wound Healing & RegenerativeMedicine Group.
"We are pleased to be presenting at this quality bioscience industryconference," said Dr. William Dolphin, Avita Medical's CEO."ReCell(R) Spray-On Skin(TM) is on the market in other countries andundergoing FDA clinical trials in the US. This conference is a greatvenue to generate awareness among the US investment community as weapproach FDA submission."
This is a one-day conference organized annually by the SouthernCalifornia Biomedical Council (SoCalBio) to showcase the strength andfuture of the bioscience industry in Los Angeles/Orange County andneighboring communities. For more information on the conference:http://www.socalbio.org/SocalBio_2012/home_2012.htm
ABOUT AVITA MEDICAL LTD. Avita Medical(http://www.avitamedical.com/) develops and distributes regenerativeand tissue-engineered products for the treatment of a broad range ofwounds, scars and skin defects. Avita's patented and proprietarytissue-culture, collection and application technology providesinnovative treatment solutions derived from a patient's own skin. Thecompany's lead product, ReCell(R) Spray-On Skin(TM), is used in awide variety of burns, plastic, reconstructive and cosmeticprocedures. ReCell is patented, CE-marked for Europe, TGA-registeredin Australia, and SFDA-cleared in China. ReCell is on market andgenerating early revenues. ReCell is not available for sale in theUnited States; in the US ReCell is an investigational device limitedby federal law to investigational use. A Phase III FDA trial is inprocess.
Contact:
Avita Medical Ltd.
Stella Sung, Ph.D.
Business Development Officer
Phone:1 838-352-9400
Email: ssung@avitamedical.com
Investor Relations:
ProActive Capital Resources Group, LLC
Jeff Ramson
CEO
641 Lexington Avenue, 6th Floor
New York, NY. 10022
Phone:1 646-863-6893
Email: jramson@proactivecapitalgroup.com
SOURCE: Avita Medical
mailto:ssung@avitamedical.com
mailto:jramson@proactivecapitalgroup.com
Copyright 2012 Marketwire, Inc., All rights reserved.
